Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: A retrospective case—control analysis

GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates

“…MPR could be calculated only for patients with more than one prescription available. Patients with MPR >80% were considered to be compliant and those with MPR≤80% were classified as non-compliant, as in previous studies [12,13,16,19,21]. Within these categories, compliance was further defined as very good (MPR≥90%), good (80% to <90%), poor (50% to <80%) and very poor (<50%).…”

“…Treatment compliance and persistence are important factors for any successful drug therapy. Several recent reports underline that a high compliance and persistence are associated with significantly higher reduction in risk of fractures in these populations [11][12][13][14][15][16]. Oral bisphosphonates are, however, associated with poor absorption, gastrointestinal adverse events and poor patient compliance [11,[17][18][19][20][21].…”

Association Between Gastrointestinal Events and Persistence with Osteoporosis Therapy: Analysis of Administrative Claims of a U.S. Managed Care Population

“…7 Peptic ulcer, chronic without hemorrhage or perforation 533. 9 Peptic ulcer, unspecified as acute or chronic, w/o hemorrhage or perforation 534.0…”

“…4 However, suboptimal compliance and low persistence to osteoporosis medication pose significant challenges for reducing the risk of fragility fracture. 5,6 Even though medication compliance is strongly linked to reduction in fracture risk, [7][8][9][10][11] several studies have indicated that compliance with osteoporosis medication is suboptimal as evidenced by a medication possession ratio less than 0.8. [12][13][14] Additionally, many patients started on osteoporosis medication do not persist with treatment.…”

“…[12][13][14] Additionally, many patients started on osteoporosis medication do not persist with treatment. 9,10,[15][16][17] Approximately 50% or more of patients newly started on bisphosphonates discontinue treatment within 12…”